Literature DB >> 20799915

Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma.

Anna E C A B Willemsen, Carla M L van Herpen, Pieter Wesseling, Peter Bult, Hanneke W M van Laarhoven.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20799915     DOI： 10.3109/0284186X.2010.491088

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  5 in total

1.  Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.

Authors:  Florence Daviet; Franck Rouby; Pascale Poullin; Julie Moussi-Francès; Marion Sallée; Stéphane Burtey; Julien Mancini; Florence Duffaud; Renaud Sabatier; Bertrand Pourroy; Aurélie Grandvuillemin; Steven Grange; Véronique Frémeaux-Bacchi; Paul Coppo; Joëlle Micallef; Noémie Jourde-Chiche
Journal:  Br J Clin Pharmacol       Date:  2018-12-18       Impact factor: 4.335

2.  Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.

Authors:  Masashi Nishikubo; Yoshimitsu Shimomura; Nobuhiro Hiramoto; Naohiko Sawamura; Takako Yamaguchi; Shigeo Hara; Takayuki Ishikawa
Journal:  BMC Nephrol       Date:  2021-05-12       Impact factor: 2.388

3.  Gemcitabine-Induced Hemolytic Uremic Syndrome in Lung Cancer: A Case Report.

Authors:  Prashant Ahlawat; Monica Gupta; Prateek Upadhyay; Shivani Gupta; Amanjot Kaur
Journal:  Cureus       Date:  2022-01-04

4.  Gemcitabine-Induced Thrombotic Microangiopathy Managed Conservatively in a Patient of Breast Cancer.

Authors:  Ghulam Mujtaba Ghumman; Huda Fatima; Tyler L Johnston; Rachel Leis; Vinod Khatri
Journal:  Cureus       Date:  2022-08-26

5.  Impact of a multidisciplinary team for the management of thrombotic microangiopathy.

Authors:  Miguel G Uriol Rivera; Sheila Cabello Pelegrin; Carmen Ballester Ruiz; Bernardo López Andrade; Javier Lumbreras; Aina Obrador Mulet; Albert Perez Montaña; Mireia Ferreruela Serlavos; José Ignacio Ayestarán Rota; Joana Ferrer Balaguer; Olga Delgado Sanchez; Lucio Pallares Ferreres; Antonio Mas Bonet; María Jose Picado Valles; Rosa María Ruíz de Gopegui Valero
Journal:  PLoS One       Date:  2018-11-02       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.